Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Report Summary

GlobalData’s new report, “Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global drug eluting stents market. The report provides market landscape, competitive landscape and market trends information on the drug eluting stents market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
• Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.
• Qualitative analysis of key market trends, market drivers, and restraints for drug eluting stents market.
• The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
• Key players covered include Abbott Laboratories, Boston Scientific, Cordis Corporation and Medtronic.

Reasons to buy

• Develop business strategies by understanding the trends and developments that are driving the drug eluting stents market globally.
• Design and develop your product development, marketing and sales strategies.
• Develop market-entry and market expansion strategies.
• Identify key players best positioned to take advantage of the emerging market opportunities.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• What’s the next big thing in the drug eluting stents market landscape? - Identify, understand and capitalize.
• Make more informed business decisions from the insightful and in-depth analysis of the global drug eluting stents market and the factors shaping it.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 GlobalData Report Guidance

3 Disease Overview - Coronary Heart Disease (CHD)
3.1 Etiology
3.2 Risk Factors
3.3 Signs and Symptoms
3.4 Diagnosis
3.4.1 Electrocardiogram (ECG)
3.4.2 Echocardiogram
3.4.3 Blood Tests
3.4.4 Coronary Angiography
3.4.5 Radionuclide tests
3.4.6 Magnetic Resonance Imaging (MRI)
3.5 Epidemiology
3.5.1 Prevalence of CHD in the US
3.5.2 Prevalence of CHD in the UK

4 Device Overview - Drug Eluting Stents (DES)
4.1 Drug Eluting Stents: Risk Factors
4.1.1 Stent Thrombosis (ST)

5 Drug Eluting Stents - Market Characterization
5.1 Drug Eluting Stents Market, Global, Revenue ($m), Historic, 2003-2010
5.2 Drug Eluting Stents Market, Global, Revenue ($m), Forecast, 2010-2017
5.3 Drug Eluting Stents Market, Global, Volume (‘000), Historic, 2003-2010
5.4 Drug Eluting Stents Market, Global, Volume (‘000), Forecast, 2010-2017
5.5 Drug Eluting Stents, Market Dynamics
5.5.1 Market Drivers
5.5.2 Market Restraints

6 Drug Eluting Stents (DES) Market, Analysis by Country, Revenue ($m), 2003-2017
6.1 Drug Eluting Stents Market, the US, Revenue ($bn), Historic, 2003-2010
6.2 Drug Eluting Stents Market, the US, Volume (million), Historic, 2003-2010
6.3 Drug Eluting Stents Market, the US, Revenue ($bn), Forecast, 2010-2017
6.4 Drug Eluting Stents Market, the US, Volume (million), Forecast, 2010-2017
6.5 Drug Eluting Stents Market, Canada, Revenue ($m), Historic, 2003-2010
6.6 Drug Eluting Stents Market, Canada, Volume (‘000), Historic, 2003-2010
6.7 Drug Eluting Stents Market, Canada, Revenue ($m), Forecast, 2010-2017
6.8 Drug Eluting Stents Market, Canada, Volume (‘000), Forecast, 2010-2017
6.9 Drug Eluting Stents Market, the UK, Revenue ($m), Historic, 2003-2010
6.10 Drug Eluting Stents Market, the UK, Volume (‘000), Historic, 2003-2010
6.11 Drug Eluting Stents Market, the UK, Revenue ($m), Forecast, 2010-2017
6.12 Drug Eluting Stents Market, the UK, Volume (‘000), Forecast, 2010-2017
6.13 Drug Eluting Stents Market, Germany, Revenue ($m), Historic, 2003-2010
6.14 Drug Eluting Stents Market, Germany, Volume (‘000), Historic, 2003-2010
6.15 Drug Eluting Stents Market, Germany, Revenue ($m), Forecast, 2010-2017
6.16 Drug Eluting Stents Market, Germany, Volume (‘000), Forecast, 2010-2017
6.17 Drug Eluting Stents Market, France, Revenue ($m), Historic, 2003-2010
6.18 Drug Eluting Stents Market, France, Volume (‘000), Historic, 2003-2010
6.19 Drug Eluting Stents Market, France, Revenue ($m), Forecast, 2010-2017
6.20 Drug Eluting Stents Market, France, Volume (‘000), Forecast, 2010-2017
6.21 Drug Eluting Stents Market, Italy, Revenue ($m), Historic, 2003-2010
6.22 Drug Eluting Stents Market, Italy, Volume (‘000), Historic, 2003-2010
6.23 Drug Eluting Stents Market, Italy, Revenue ($m), Forecast, 2010-2017
6.24 Drug Eluting Stents Market, Italy, Volume (‘000), Forecast, 2010-2017
6.25 Drug Eluting Stents Market, Spain, Revenue ($m), Historic, 2003-2010
6.26 Drug Eluting Stents Market, Spain, Volume (‘000), Historic, 2003-2010
6.27 Drug Eluting Stents Market, Spain, Revenue ($m), Forecast, 2010-2017
6.28 Drug Eluting Stents Market, Spain, Volume (‘000), Forecast, 2010-2017
6.29 Drug Eluting Stents Market, Japan, Revenue ($m), Historic, 2003—2010
6.30 Drug Eluting Stents Market, Japan, Volume (‘000), Historic, 2003—2010
6.31 Drug Eluting Stents Market, Japan, Revenue ($m), Forecast, 2010—2017
6.32 Drug Eluting Stents Market, Japan, Volume (‘000), Forecast, 2010—2017
6.33 Drug Eluting Stents Market, China, Revenue ($m), Historic, 2003—2010
6.34 Drug Eluting Stents Market, China, Volume (‘000), Historic, 2003—2010
6.35 Drug Eluting Stents Market, China, Revenue ($m), Forecast, 2010—2017
6.36 Drug Eluting Stents Market, China, Volume (‘000), Forecast, 2010—2017
6.37 Drug Eluting Stents Market, India, Revenue ($m), Historic, 2003—2010
6.38 Drug Eluting Stents Market, India, Volume (‘000), Historic, 2003—2010
6.39 Drug Eluting Stents Market, India, Revenue ($m), Forecast, 2010—2017
6.40 Drug Eluting Stents Market, India, Volume (‘000), Forecast, 2010-2017
6.41 Drug Eluting Stents Market, Australia, Revenue ($m), Historic, 2003-2010
6.42 Drug Eluting Stents Market, Australia, Volume (‘000), Historic, 2003-2010
6.43 Drug Eluting Stents Market, Australia, Revenue ($m), Forecast, 2010-2017
6.44 Drug Eluting Stents Market, Australia, Volume (‘000), Forecast, 2010-2017
6.45 Drug Eluting Stents Market, Brazil, Revenue ($m), Historic, 2003-2010
6.46 Drug Eluting Stents Market, Brazil, Volume (‘000), Historic, 2003-2010
6.47 Drug Eluting Stents Market, Brazil, Revenue ($m), Forecast, 2010-2017
6.48 Drug Eluting Stents Market, Brazil, Volume (‘000), Forecast, 2010-2017

7 Drug Eluting Stents Market - Strategic Competitive Assessment
7.1 Drug Eluting Stents Market: Key Player Profiles
7.1.1 Boston Scientific
7.1.2 Abbott Laboratories
7.1.3 Medtronic Inc.
7.1.4 Cordis Corporation

8 Drug Eluting Stents - Key Marketed Products
8.1 TAXUS Liberté Paclitaxel-Eluting Coronary Stent System
8.1.1 Product Description
8.1.2 Features and Benefits
8.2 PROMUS Everolimus-Eluting Coronary Stent System
8.2.1 Product Description
8.2.2 Features and Benefits
8.3 XIENCE V Everolimus-Eluting Coronary Stent System
8.3.1 Product Description
8.3.2 Features and Benefits
8.4 CYPHER Sirolimus-Eluting Coronary Stent
8.4.1 Product Description
8.4.2 Features and Benefits
8.5 Endeavor Zotarolimus-Eluting Stent System
8.5.1 Product Description
8.5.2 Features and Benefits

9 Drug Eluting Stents Market - Strategic Pipeline Assessment
9.1 Bioabsorbable Drug-eluting Stents
9.1.1 Key Pipeline Products
9.2 Drug Eluting Stents, Pipeline Assessment, by Development Stage
9.3 Profiles of Promising Products under Clinical Development
9.3.1 TAXUS Element (ION) Paclitaxel-Eluting Coronary Stent System
9.3.2 XIENCE PRIME Everolimus-Eluting Coronary Stent System
9.3.3 JACTAX Drug-eluting Stent
9.3.4 PROMUS Element Everolimus-Eluting Coronary Stent
9.3.5 Synergy Coronary Stent
9.3.6 AVJ-09-385
9.3.7 ZoMaxx Drug Eluting Coronary Stent System
9.3.8 NEVO Sirolimus-Eluting Coronary Stent
9.3.9 Endeavor Resolute

10 Drug Eluting Stents Market - Deals Landscape
10.1 Drug Eluting Stents Marke - Deals Overview
10.2 Key Deals (2009-2010)
10.2.1 Biosensors International Group Acquired Assets from Devax
10.2.2 Xenogenics Acquired Assets of Ideal BioStent
10.2.3 Biosensors International acquires CardioMind
10.2.4 Boston Scientific acquires Labcoat
10.2.5 Svelte Medical Systems enters into Licensing Agreement with Cordis

11 Appendix
11.1 Definitions
11.1.1 Drug Eluting Stent (DES)
11.2 Abbreviations (in alphabetical order)
11.3 Research Methodology
11.3.1 Secondary Research
11.3.2 Primary Research
11.3.3 Models
11.3.4 Forecasts
11.3.5 Expert Panel
11.4 GlobalData Consulting
11.5 Contact Us
11.6 Disclaimer
11.7 Sources

List of Tables

Table 1: Drug Eluting Stents, Classified by Drug Used, 2010
Table 2: Drug Eluting Stents Market, Global, Revenue ($m), 2003-2010
Table 3: Drug Eluting Stents Market, Global, Revenue ($m), 2010-2017
Table 4: Drug Eluting Stents Market, Global, Volume (‘000), 2003-2010
Table 5: Drug Eluting Stents Market, Global, Volume (‘000), 2010-2017
Table 6: Coronary Heart Disease, the US, Prevalence (%), 2010-2030
Table 7: Coronary Heart Disease in Men by Age, the UK, Prevalence (%), 2000-2008
Table 8: Coronary Heart Disease in Women by Age, the UK, Prevalence (%), 2000-2008
Table 9: Population Aged 65 and Above, Global, Population (million), 2004-2010
Table 10: Population Aged 60 and Above, the US, Population (million) and Population Aged 60 and Above as a Percentage (%) of Adult Population, 2000-2050
Table 11: Prevalence of Coronary Heart Disease in Population Aged between 60-79 and Population Aged 80 and Above, the US, Prevalence (%), 2006
Table 12: Population Aged 65 and above, the UK, Population (million) and Population Aged 65 and Above as a Percentage (%) of Adult Population, 2000-2050
Table 13: Coronary Heart Disease in Men Aged 65 and Above, the UK, Prevalence (%), 2000-2008
Table 14: Coronary Heart Disease in Women Aged 65 and Above, the UK, Prevalence (%), 2000-2008
Table 15: Tobacco Consumption, Global, Population (billion), 2000—2050
Table 16: Diabetes Prevalence, by Country, Prevalence (%), Latest Data Available
Table 17: Percutaneous Coronary Intervention Procedure (million), Global, 2003-2010
Table 18: Percutaneous Coronary Intervention Procedure (million), the US, 2003-2010
Table 19: Percutaneous Coronary Intervention Procedure (‘000), Europe, 2003-2010
Table 20: Drug Eluting Stents Market, by Country, Average Selling Price ($), 2003-2010
Table 21: Drug Eluting Stents Market, the US, Revenue ($bn), 2003-2010
Table 22: Drug Eluting Stents Market, the US, Volume (million), 2003-2010
Table 23: Drug Eluting Stents Market, the US, Revenue ($bn), 2010-2017
Table 24: Drug Eluting Stents Market, the US, Volume (million), 2010-2017
Table 25: Drug Eluting Stents Market, Canada, Revenue ($m), 2003-2010
Table 26: Drug Eluting Stents Market, Canada, Volume (‘000), 2003-2010
Table 27: Drug Eluting Stents Market, Canada, Revenue ($m), 2010-2017
Table 28: Drug Eluting Stents Market, Canada, Volume (‘000), 2010-2017
Table 29: Drug Eluting Stents Market, the UK, Revenue ($m), 2003-2010
Table 30: Drug Eluting Stents Market, the UK, Volume (‘000), 2003-2010
Table 31: Drug Eluting Stents Market, the UK, Revenue ($m), 2010-2017
Table 32: Drug Eluting Stents Market, the UK, Volume (‘000), 2010-2017
Table 33: Drug Eluting Stents Market, Germany, Revenue ($m), 2003-2010
Table 34: Drug Eluting Stents Market, Germany, Volume (‘000), 2003-2010
Table 35: Drug Eluting Stents Market, Germany, Revenue ($m), 2010-2017
Table 36: Drug Eluting Stents Market, Germany, Volume (‘000), 2010-2017
Table 37: Drug Eluting Stents Market, France, Revenue ($m), 2003-2010
Table 38: Drug Eluting Stents Market, France, Volume (‘000), 2003-2010
Table 39: Drug Eluting Stents Market, France, Revenue ($m), 2010-2017
Table 40: Drug Eluting Stents Market, France, Volume (‘000), 2010-2017
Table 41: Drug Eluting Stents Market, Italy, Revenue ($m), 2003-2010
Table 42: Drug Eluting Stents Market, Italy, Volume (‘000), 2003-2010
Table 43: Drug Eluting Stents Market, Italy, Revenue ($m), 2010-2017
Table 44: Drug Eluting Stents Market, Italy, Volume (‘000), 2010-2017
Table 45: Drug Eluting Stents Market, Spain, Revenue ($m), 2003-2010
Table 46: Drug Eluting Stents Market, Spain, Volume (‘000), 2003-2010
Table 47: Drug Eluting Stents Market, Spain, Revenue ($m), 2010-2017
Table 48: Drug Eluting Stents Market, Spain, Volume (‘000), 2010-2017
Table 49: Drug Eluting Stents Market, Japan, Revenue ($m), 2003—2010
Table 50: Drug Eluting Stents Market, Japan, Volume (‘000), 2003—2010
Table 51: Drug Eluting Stents Market, Japan, Revenue ($m), 2010—2017
Table 52: Drug Eluting Stents Market, Japan, Volume (‘000), 2010—2017
Table 53: Drug Eluting Stents Market, China, Revenue ($m), 2003—2010
Table 54: Drug Eluting Stents Market, China, Volume (‘000), 2003—2010
Table 55: Drug Eluting Stents Market, China, Revenue ($m), 2010—2017
Table 56: Drug Eluting Stents Market, China, Volume (‘000), 2010—2017
Table 57: Drug Eluting Stents Market, India, Revenue ($m), 2003—2010
Table 58: Drug Eluting Stents Market, India, Volume (‘000), 2003—2010
Table 59: Drug Eluting Stents Market, India, Revenue ($m), 2010—2017
Table 60: Drug Eluting Stents Market, India, Volume (‘000), 2010-2017
Table 61: Drug Eluting Stents Market, Australia, Revenue ($m), 2003-2010
Table 62: Drug Eluting Stents Market, Australia, Volume (‘000), 2003-2010
Table 63: Drug Eluting Stents Market, Australia, Revenue ($m), 2010-2017
Table 64: Drug Eluting Stents Market, Australia, Volume (‘000), 2010-2017
Table 65: Drug Eluting Stents Market, Brazil, Revenue ($m), 2003-2010
Table 66: Drug Eluting Stents Market, Brazil, Volume (‘000), 2003-2010
Table 67: Drug Eluting Stents Market, Brazil, Revenue ($m), 2010-2017
Table 68: Drug Eluting Stents Market, Brazil, Volume (‘000), 2010-2017
Table 69: Drug Eluting Stents Market, Global, Company Share ($m), 2010
Table 70: Boston Scientific Marketed Products, 2011
Table 71: Boston Scientific Pipeline Products, 2011
Table 72: Abbott Laboratories Marketed Products, 2011
Table 73: Abbott Laboratories Pipeline Products, 2011
Table 74: Medtronic Inc. Marketed Products, 2011
Table 75: Medtronic Inc. Pipeline Products, 2011
Table 76: Cordis Corporation Marketed Products, 2011
Table 77: Cordis Corporation Pipeline Products, 2011
Table 78: Absorb Product Status
Table 79: Absorb Clinical Trial 1
Table 80: Absorb Clinical Trial 2
Table 81: Absorb Clinical Trial 3
Table 82: Bioresorbable Stent Product Status
Table 83: Biosorb Product Status
Table 84: Drug Eluting Absorbable Metal Scaffold Product Status
Table 85: Drug Eluting Absorbable Metal Scaffold Clinical Trials
Table 86: Fully Biodegradable Stent Product Status
Table 87: IDEAL Stent Product Status
Table 88: Myolimus-Eluting Coronary Stent - Bioabsorbable Polymer Product Status
Table 89: Myolimus-Eluting Coronary Stent - Bioabsorbable Polymer Clinical Trials
Table 90: Peptide-Eluting Coronary Stent Product Status
Table 91: RESORB Product Status
Table 92: ReZolve Bioresorbable Coronary Stent Product Status
Table 93: ReZolve Bioresorbable Coronary Stent Clinical Trials
Table 94: TephaFLEX Absorbable Stent Product Status
Table 95: Whisper Coronary Stent System Product Status
Table 96: Whisper Coronary Stent System Clinical Trials
Table 97: Product Status
Table 98: TAXUS Element Clinical Trial 1
Table 99: TAXUS Element Clinical Trial 2
Table 100: TAXUS Element Clinical Trial 3
Table 101: Product Status
Table 102: XIENCE PRIME Clinical Trial 1
Table 103: DARE Trial
Table 104: XIENCE PRIME Clinical Trial 3
Table 105: XIENCE PRIME Clinical Trial 4
Table 106: XIENCE PRIME Clinical Trial 5
Table 107: Product Status
Table 108: JACTAX Clinical Trial 1
Table 109: JACTAX Clinical Trial 2
Table 110: JACTAX Clinical Trial 3
Table 111: Product Status
Table 112: PROMUS Clinical Trial 1
Table 113: PROMUS Clinical Trial 2
Table 114: PROMUS Clinical Trial 3
Table 115: PROMUS Clinical Trial 4 (EVOLVE)
Table 116: PROMUS Clinical Trail 5
Table 117: PROMUS Clinical Trial 6
Table 118: Product Status
Table 119: Synergy Clinical Trial (EVOLVE)
Table 120: Product Status
Table 121: AVJ-09-385 Clinical Trial
Table 122: Product Status
Table 123: ZoMaxx Clinical Trial
Table 124: Product Status
Table 125: NEVO Clinical Trial 1
Table 126: NEVO Clinical Trial 2
Table 127: NEVO Clinical Trial 3
Table 128: NEVO Clinical Trial 4
Table 129: NEVO Clinical Trial 5
Table 130: NEVO Clinical Trial 6
Table 131: Product Status
Table 132: Endeavor Resolute Clinical Trial 1
Table 133: Endeavor Resolute Clinical Trial 2
Table 134: Endeavor Resolute Clinical Trial 3
Table 135: Endeavor Resolute Clinical Trial 4
Table 136: Endeavor Resolute Clinical Trial 5
Table 137: Endeavor Resolute Clinical Trial 6
Table 138: Endeavor Resolute Clinical Trial 7
Table 139: Endeavor Resolute Clinical Trial 8
Table 140: Endeavor Resolute Clinical Trial 9
Table 141: Endeavor Resolute Clinical Trial 10

List of Figures

Figure 1: Coronary Heart Disease, Signs and Symptoms
Figure 2: Drug Eluting Stents Market, Global, Revenue ($m), 2003-2010
Figure 3: Drug Eluting Stents Market, Global, Revenue ($m), 2010-2017
Figure 4: Drug Eluting Stents Market, Global, Volume (‘000), 2003-2010
Figure 5: Drug Eluting Stents Market, Global, Volume (‘000), 2010-2017
Figure 6: Drug Eluting Stents, Global, Market Dynamics
Figure 7: Coronary Heart Disease, the US, Prevalence (%), 2010-2030
Figure 8: Coronary Heart Disease in Men by Age, the UK, Prevalence (%), 2000-2008
Figure 9: Coronary Heart Disease in Women by Age, the UK, Prevalence (%), 2000-2008
Figure 10: Population Aged 65 and Above, Global, Population (million), 2004-2010
Figure 11: Population Aged 60 and Above, the US, Population (million) and Population Aged 60 and Above as a Percentage (%) of Adult Population, 2000-2050
Figure 12: Prevalence of Coronary Heart Disease in Population Aged between 60-79 and Population Aged 80 and Above, the US, Prevalence (%), 2006
Figure 13: Population Aged 65 and above, the UK, Population (million) and Population Aged 65 and Above as a Percentage (%) of Adult Population, 2000-2050
Figure 14: Coronary Heart Disease in Men Aged 65 and Above, the UK, Prevalence (%), 2000-2008
Figure 15: Coronary Heart Disease in Women Aged 65 and Above, the UK, Prevalence (%), 2000-2008
Figure 16: Tobacco Consumption, Global, Population (billion), 2000—2050
Figure 17: Percutaneous Coronary Intervention Procedure (million), Global, 2003-2010
Figure 18: Percutaneous Coronary Intervention Procedure (million), the US, 2003-2010
Figure 19: Percutaneous Coronary Intervention Procedure (‘000), Europe, 2003-2010
Figure 20: Drug Eluting Stents, the US and the UK, Average Selling Price ($), 2003-2010
Figure 21: Drug Eluting Stents Market, the US, Revenue ($bn), 2003-2010
Figure 22: Drug Eluting Stents Market, the US, Volume (million), 2003-2010
Figure 23: Drug Eluting Stents Market, the US, Revenue ($bn), 2010-2017
Figure 24: Drug Eluting Stents Market, the US, Volume (million), 2010-2017
Figure 25: Drug Eluting Stents Market, Canada, Revenue ($m), 2003-2010
Figure 26: Drug Eluting Stents Market, Canada, Volume (‘000), 2003-2010
Figure 27: Drug Eluting Stents Market, Canada, Revenue ($m), 2010-2017
Figure 28: Drug Eluting Stents Market, Canada, Volume (‘000), 2010-2017
Figure 29: Drug Eluting Stents Market, the UK, Revenue ($m), 2003-2010
Figure 30: Drug Eluting Stents Market, the UK, Volume (‘000), 2003-2010
Figure 31: Drug Eluting Stents Market, the UK, Revenue ($m), 2010-2017
Figure 32: Drug Eluting Stents Market, the UK, Volume (‘000), 2010-2017
Figure 33: Drug Eluting Stents Market, Germany, Revenue ($m), 2003-2010
Figure 34: Drug Eluting Stents Market, Germany, Volume (‘000), 2003-2010
Figure 35: Drug Eluting Stents Market, Germany, Revenue ($m), 2010-2017
Figure 36: Drug Eluting Stents Market, Germany, Volume (‘000), 2010-2017
Figure 37: Drug Eluting Stents Market, France, Revenue ($m), 2003-2010
Figure 38: Drug Eluting Stents Market, France, Volume (‘000), 2003-2010
Figure 39: Drug Eluting Stents Market, France, Revenue ($m), 2010-2017
Figure 40: Drug Eluting Stents Market, France, Volume (‘000), 2010-2017
Figure 41: Drug Eluting Stents Market, Italy, Revenue ($m), 2003-2010
Figure 42: Drug Eluting Stents Market, Italy, Volume (‘000), 2003-2010
Figure 43: Drug Eluting Stents Market, Italy, Revenue ($m), 2010-2017
Figure 44: Drug Eluting Stents Market, Italy, Volume (‘000), 2010-2017
Figure 45: Drug Eluting Stents Market, Spain, Revenue ($m), 2003-2010
Figure 46: Drug Eluting Stents Market, Spain, Volume (‘000), 2003-2010
Figure 47: Drug Eluting Stents Market, Spain, Revenue ($m), 2010-2017
Figure 48: Drug Eluting Stents Market, Spain, Volume (‘000), 2010-2017
Figure 49: Drug Eluting Stents Market, Japan, Revenue ($m), 2003—2010
Figure 50: Drug Eluting Stents Market, Japan, Volume (‘000), 2003—2010
Figure 51: Drug Eluting Stents Market, Japan, Revenue ($m), 2010—2017
Figure 52: Drug Eluting Stents Market, Japan, Volume (‘000), 2010—2017
Figure 53: Drug Eluting Stents Market, China, Revenue ($m), 2003—2010
Figure 54: Drug Eluting Stents Market, China, Volume (‘000), 2003—2010
Figure 55: Drug Eluting Stents Market, China, Revenue ($m), 2010—2017
Figure 56: Drug Eluting Stents Market, China, Volume (‘000), 2010—2017
Figure 57: Drug Eluting Stents Market, India, Revenue ($m), 2003—2010
Figure 58: Drug Eluting Stents Market, India, Volume (‘000), 2003—2010
Figure 59: Drug Eluting Stents Market, India, Revenue ($m), 2010—2017
Figure 60: Drug Eluting Stents Market, India, Volume (‘000), 2010-2017
Figure 61: Drug Eluting Stents Market, Australia, Revenue ($m), 2003-2010
Figure 62: Drug Eluting Stents Market, Australia, Volume (‘000), 2003-2010
Figure 63: Drug Eluting Stents Market, Australia, Revenue ($m), 2010-2017
Figure 64: Drug Eluting Stents Market, Australia, Volume (‘000), 2010-2017
Figure 65: Drug Eluting Stents Market, Brazil, Revenue ($m), 2003-2010
Figure 66: Drug Eluting Stents Market, Brazil, Volume (‘000), 2003-2010
Figure 67: Drug Eluting Stents Market, Brazil, Revenue ($m), 2010-2017
Figure 68: Drug Eluting Stents Market, Brazil, Volume (‘000), 2010-2017
Figure 69: Drug Eluting Stents Market, Global, Company Share (%), 2010
Figure 70: Boston Scientific Corporation, SWOT Analysis
Figure 71: Abbott Laboratories, SWOT Analysis
Figure 72: Medtronic Inc., SWOT Analysis
Figure 73: Cordis Corporation, SWOT Analysis
Figure 74: Drug Eluting Stents Market, Key Marketed Products
Figure 75: Pipeline Products, by Development Stage, 2011
Figure 76: Drug Eluting Stents, Deals Landscape, 2009-2010